Outsmarting Cancer to Deliver More Cures

CARGO is developing next-generation transformational CAR T-cell therapies with the mission of outsmarting cancer to deliver more cures for patients.

Science

News

CARGO Therapeutics to Participate in Upcoming Investor Conferences

Read More ⟶

CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma Activity

Read More ⟶

CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Read More ⟶

Life at CARGO

CARGO Therapeutics is Now Hiring. Join us to make a difference.
Open Positions ⟶